Funding for this research was provided by:
novartis pharmaceuticals corporation
Received: 9 September 2021
Accepted: 28 February 2022
First Online: 18 March 2022
: Survey materials and the study protocol were reviewed and approved by a centralized Institutional Review Board (IRB). Patients and physicians were given an overview of the study and the ethical approval details; those who wished to participate were required to provide consent via a tick/check box before initiation.
: Not applicable.
: Dr. Shashank Udupi is a full-time employee of Novartis Healthcare Private Limited. None of the other authors had any conflict of interest to declare.